UBS Group AG - DIFFUSION PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
UBS Group AG ownership history of DIFFUSION PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2022$0
-100.0%
1
-100.0%
0.00%
Q4 2021$16,000
+1500.0%
52,652
+2414.4%
0.00%
Q3 2021$1,000
-96.3%
2,094
-94.3%
0.00%
Q2 2021$27,000
-74.0%
36,910
-67.3%
0.00%
Q1 2021$104,000
+1980.0%
112,927
+1782.4%
0.00%
Q4 2020$5,000
-76.2%
5,999
-75.9%
0.00%
Q3 2020$21,000
-32.3%
24,845
-20.6%
0.00%
Q2 2020$31,000
+55.0%
31,302
-49.6%
0.00%
Q1 2020$20,000
+5.3%
62,067
+48.4%
0.00%
Q4 2019$19,000
+90.0%
41,821
+670.5%
0.00%
Q3 2019$10,000
-23.1%
5,428
+55.2%
0.00%
Q1 2019$13,000
+333.3%
3,497
+113.4%
0.00%
Q4 2018$3,0001,6390.00%
Other shareholders
DIFFUSION PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Yu Fan 89,848$66,0000.75%
Virtu Financial LLC 285,621$209,0000.02%
GSA CAPITAL PARTNERS LLP 30,180$22,0000.00%
WILBANKS SMITH & THOMAS ASSET MANAGEMENT LLC 43,868$32,0000.00%
Hoover Financial Advisors, Inc. 4,225$3,0000.00%
Renaissance Technologies 1,375,579$1,004,0000.00%
Frontier Wealth Management LLC 25,000$18,0000.00%
UBS Group AG 36,910$27,0000.00%
IFP Advisors, Inc 0$00.00%
OSAIC HOLDINGS, INC. 29,569$22,0000.00%
View complete list of DIFFUSION PHARMACEUTICALS IN shareholders